Functional improvement of dystrophic muscle by myostatin blockade
The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Mice and cattle with mutations in the myostatin (GDF8) gene show a marked increase in body weight and muscle mass, indicating that this new member of the TGF-beta superfamily is a negative regulator of skeletal muscle growth. Inhibition of the myostatin gene product is predicted to increase muscle mass and improve the disease phenotype in a variety of primary and secondary myopathies. We tested the ability of inhibition of myostatin in vivo to ameliorate the dystrophic phenotype in the mdx mouse model of Duchenne muscular dystrophy (DMD). Blockade of endogenous myostatin by using intraperitoneal injections of blocking antibodies for three months resulted in an increase in body weight, muscle mass, muscle size and absolute muscle strength in mdx mouse muscle along with a significant decrease in muscle degeneration and concentrations of serum creatine kinase. The functional improvement of dystrophic muscle by myostatin blockade provides a novel, pharmacological strategy for treatment of diseases associated with muscle wasting such as DMD, and circumvents the major problems associated with conventional gene therapy in these disorders.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The interest in myostatin was generated by recent studies where antibodies for myostatin were created and administered to adult rodents, which resulted in an increase in body mass, muscle mass, muscle size, and strength [11,12].”
From Effects of methoxyisoflavone, ecdysterone, and sulfo-polysaccharide supplementation on training adaptations in resistance-trained males (2006) · cites this paper as [12]
Citations
Cites
Textbook of Medical Physiology
(1966) · Annals of Internal Medicine · doi:10.7326/0003-4819-64-6-1363_2 · Cited by 9,749
Dystrophin: the protein product of the Duchenne muscular dystrophy locus
Hoffman, E. P., Brown, R. H., & Kunkel, L. M. (1987) · Cell · doi:10.1016/0092-8674(87)90579-4 · Cited by 4,693
Regulation of skeletal muscle mass in mice by a new TGF-p superfamily member
McPherron, A. C., Lawler, A. M., & Lee, S.-J. (1997) · Nature · doi:10.1038/387083a0 · Cited by 4,013
TEXTBOOK OF MEDICAL PHYSIOLOGY
GUYTON, A. C. (1967) · The American Journal of the Medical Sciences · doi:10.1097/00000441-196701000-00031 · Cited by 2,837
Dystrophin expression in the mdx mouse restored by stem cell transplantation
Gussoni, E., Soneoka, Y., Strickland, C. D., Buzney, E. A., Khan, M. K., Flint, A. F., Kunkel, L. M., & Mulligan, R. C. (1999) · Nature · doi:10.1038/43919 · Cited by 1,802 · cited 1×
“In comparison with conventional transgenic, cell and gene therapy approache”
BackgroundX chromosome-linked muscular dystrophy (mdx) in the mouse
Bulfield, G., Siller, W. G., Wight, P. A., & Moore, K. J. (1984) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.81.4.1189 · Cited by 1,765
Regulation of myostatin activity and muscle growth
Lee, S.-J., & McPherron, A. C. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.151270098 · Cited by 1,616 · cited 1×
“Alterations in Smad 2 and 3 phosphorylation would be predicted to regulate the formation of Smad complexes, their nuclear translocation and transcriptional regulation of genes associated with commitment of muscle progenitor”
BackgroundA deletion in the bovine myostatin gene causes the double–muscled phenotype in cattle
Grobet, L., Royo Martin, L. J., Poncelet, D., Pirottin, D., Brouwers, B., Riquet, J., Schoeberlein, A., Dunner, S., Ménissier, F., Massabanda, J., et al. (1997) · Nature Genetics · doi:10.1038/ng0997-71 · Cited by 1,556
Dystrophin protects the sarcolemma from stresses developed during muscle contraction
Petrof, B. J., Shrager, J. B., Stedman, H. H., Kelly, A. M., & Sweeney, H. L. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3710 · Cited by 1,526 · cited 1×
“The regimen did not completely reverse dystrophic changes; physiological parameters evaluated by ex vivo tests, such as susceptibility to damage by lengthening contraction”
BackgroundAhima, R. S., & Flier, J. S. (2000) · Annual Review of Physiology · doi:10.1146/annurev.physiol.62.1.413 · Cited by 1,428
Self-citation
Research works printed but not linked: 2
- Jalenak, M. et al. Transcriptional changes arising from in vivo inhibition of myostatin. J. Neurol. Sci. 199 (suppl)., S83 (2002)
- Engel, A. G. & Franzini-Armstrong, C. Myology (McGraw-Hill, New York, 1994)
Cited by
Items 201–300 of 853
Cudré-Mauroux, C., Occhiodoro, T., König, S., Salmon, P., Bernheim, L., & Trono, D. (2003) · Human Gene Therapy · doi:10.1089/104303403322495034 · Cited by 87
Bartoli, M., Poupiot, J., Vulin, A., Fougerousse, F., Arandel, L., Danièle, N., Roudaut, C., Noulet, F., García, L., Danos, O., et al. (2007) · Gene Therapy · doi:10.1038/sj.gt.3302928 · Cited by 89
Morrison, B. M., Lachey, J. L., Warsing, L. C., Ting, B. L., Pullen, A. E., Underwood, K. W., Kumar, R., Sako, D., Grinberg, A. V., Wong, V. L., et al. (2009) · Experimental Neurology · doi:10.1016/j.expneurol.2009.02.017 · Cited by 90
Myostatin: a skeletal muscle chalone
Lee, S.-J. (2023) · Annual Review of Physiology · doi:10.1146/annurev-physiol-012422-112116 · Cited by 84
Functional and Morphological Improvement of Dystrophic Muscle by Interleukin 6 Receptor Blockade
Pelosi, L., Berardinelli, M. G., Pasquale, L. D., Nicoletti, C., D’Amico, A., Carvello, F., Moneta, G. M., Catizone, A., Bertini, E., Benedetti, F. D., et al. (2015) · EBioMedicine · doi:10.1016/j.ebiom.2015.02.014 · Cited by 86
“…necrosis only early in neonatal life, it remains an ideal model for preclinical tests and proof-of-concept studies (Bentzinger et al., 2014; Bogdanovich et al., 2002; Colussi et al., 2008; Consalvi et al., 2013; Denti et al., 2006; Grounds et al., 2008; Jiang et al., 2014; al Embryology,…”
BackgroundSignalling and the control of skeletal muscle size
Otto, A., & Patel, K. (2010) · Experimental Cell Research · doi:10.1016/j.yexcr.2010.04.009 · Cited by 100
Blaauw, B., Mammucari, C., Toniolo, L., Agatea, L., Abraham, R., Sandri, M., Reggiani, C., & Schiaffino, S. (2008) · Human Molecular Genetics · doi:10.1093/hmg/ddn264 · Cited by 86
Gene and cell‐mediated therapies for muscular dystrophy
Konieczny, P., Swiderski, K., & Chamberlain, J. S. (2013) · Muscle & Nerve · doi:10.1002/mus.23738 · Cited by 97
Effect of RNA oligonucleotide targeting Foxo-1 on muscle growth in normal and cancer cachexia mice
Cm, L., Yang, Z., Liu, C.-W., Wang, R., Tien, P., Dale, R., & Sun, L.-Q. (2007) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7701091 · Cited by 83
Rossi, G., Antonini, S., Bonfanti, C., Monteverde, S., Vezzali, C., Tajbakhsh, S., Cossu, G., & Messina, G. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.02.014 · Cited by 81
“Although interference of this pathway was reported to lead to functional improvement of dystrophic muscles in mice (Bogda- novich et al., 2002), the precise mode of action of this powerful signaling pathway as a potential therapeutic agent for myopa- thies remains unclear.”
BackgroundThe new frontier in muscular dystrophy research: booster genes
Engvall, E., & Wewer, U. M. (2003) · The FASEB Journal · doi:10.1096/fj.02-1215rev · Cited by 91
“(35) blocked myostatin in young mdx mice by intraperitoneal injections of a neutralizing antibody.”
BackgroundNovel therapies for Duchenne muscular dystrophy
Kapsa, R. M. I., Kornberg, A. J., & Byrne, E. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00382-x · Cited by 91
Dumonceaux, J., Marie, S., Beley, C., Trollet, C., Vignaud, A., Ferry, A., Butler-Browne, G. S., & García, L. (2010) · Molecular Therapy · doi:10.1038/mt.2009.322 · Cited by 84
Stem cells to tissue: molecular, cellular and anatomical heterogeneity in skeletal muscle
Tajbakhsh, S. (2003) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(03)00090-x · Cited by 92
Skeletal Muscle Degenerative Diseases and Strategies for Therapeutic Muscle Repair
Tabebordbar, M., Wang, E. T., & Wagers, A. J. (2013) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011811-132450 · Cited by 79
“Delivery of a monoclonal antibody against myostatin into mdx mice resulted in increased body weight, muscle mass, and strength; however, resistance to contraction-induced injury was not improved according to ex vivo evaluations (220).”
BackgroundDuchenne Muscular Dystrophy Gene Therapy in the Canine Model
Duan, D. (2015) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2015.006 · Cited by 89
Myostatin: a modulator of skeletal-muscle stem cells
Walsh, F. S., & Celeste, A. J. (2005) · Biochemical Society Transactions · doi:10.1042/bst0331513 · Cited by 77
Mdx respiratory impairment following fibrosis of the diaphragm
Ishizaki, M., Suga, T., Kimura, E., Shiota, T., Kawano, R., Uchida, Y., Uchino, K., Yamashita, S., Maeda, Y., & Uchino, M. (2008) · Neuromuscular Disorders · doi:10.1016/j.nmd.2008.02.002 · Cited by 78
“Recent advances have identified many possible therapeutic approaches including pharmacological treatments [11] such as the use of myostatin antibodies [12,13], gene therapies and cell therapy with different types of newly identified stem cells [14].”
BackgroundCancer Cachexia: It’s Time for More Clinical Trials
Bossola, M., Pacelli, F., Tortorelli, A. P., & Doglietto, G. B. (2006) · Annals of Surgical Oncology · doi:10.1245/s10434-006-9179-5 · Cited by 85
“muscle function and reduced muscle degeneration in dystrophic mice.(81,82) Indeed, in the study of Bogdanovich et al.”
BackgroundWenzel, K., Zabojszcza, J., Carl, M., Taubert, S., Lass, A., Harris, C. L., Ho, M., Schulz, H., Hummel, O., Hübner, N., et al. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.9.6219 · Cited by 89
“The muscle hypertrophy has raised some hope about the possible suitability of myostatin as a therapeutic target in muscular dystrophies (60).”
BackgroundInhibition of myostatin does not ameliorate disease features of severe spinal muscular atrophy mice
Sumner, C. J., Wee, C. D., Warsing, L. C., Choe, D. W., Ng, A. S., Lutz, C. M., & Wagner, K. R. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddp253 · Cited by 84
“Loss or blockade of myostatin signaling by genetic deletion (33), neutralizing monoclonal antibody (34) or inhibitory myostatin propeptide (29,30) ameliorates the disease features in the Duchenne and Becker muscular dystrophy mdx mouse model lacking dystrophin.”
BackgroundThe TGF-β Signalling Network in Muscle Development, Adaptation and Disease
Chen, J. L., Colgan, T. D., Walton, K. L., Gregorevic, P., & Harrison, C. A. (2016) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-27511-6_5 · Cited by 88
Bogdanovich, S., McNally, E. M., & Khurana, T. S. (2008) · Muscle & Nerve · doi:10.1002/mus.20920 · Cited by 74
Self-citationCassano, M., Biressi, S., Finan, A., Benedetti, L., Omes, C., Boratto, R., Martin, F., Allegretti, M., Broccoli, V., Angelis, M. G. C. D., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003223 · Cited by 77
“Biochemical and molecular analysis Western blot analysis of cells or tissues was performed as described [41], 55.”
BackgroundMethodGehrig, S. M., Koopman, R., Naim, T., Tjoakarfa, C., & Lynch, G. S. (2009) · American Journal Of Pathology · doi:10.2353/ajpath.2010.090760 · Cited by 81
Anti-inflammatory drugs for Duchenne muscular dystrophy: focus on skeletal muscle-releasing factors
Aoki, Y., Miyatake, S., Shimizu‐Motohashi, Y., & Takeda, S. (2016) · Drug Design Development and Therapy · doi:10.2147/dddt.s110163 · Cited by 85
“108 In contrast, a double-blind randomized clinical trial in Becker muscular dystrophy indicated that MYO-029 was safe but not efficacious.”
Flanigan, K. M. (2012) · Seminars in Neurology · doi:10.1055/s-0032-1329199 · Cited by 90
Myostatin, a negative regulator of muscle mass: implications for muscle degenerative diseases
Tobin, J. F., & Celeste, A. J. (2005) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2005.01.011 · Cited by 89
Stupka, N., Plant, D. R., Schertzer, J. D., Emerson, T. M., Bassel‐Duby, R., Olson, E. N., & Lynch, G. S. (2006) · The Journal of Physiology · doi:10.1113/jphysiol.2006.108472 · Cited by 85
“Both interventions decreased muscle membrane damage in mdx mice, but did not reduce susceptibility to contraction-induced injury (Granata et al. 1998; Barton et al. 2002; Bogdanovich et al. 2002) nor the incidence of centrally nucleated fibres (Bogdanovich et al. 2002).”
BackgroundMeinen, S., Barzaghi, P., Lin, S., Lochmüller, H., & Rüegg, M. A. (2007) · The Journal of Cell Biology · doi:10.1083/jcb.200611152 · Cited by 79
“Such routes for mini-agrin could be viral vectors (Qiao et al., 2005), but also injection of recombinant protein, as done for other muscle diseases (Bogdanovich et al., 2002; Raben et al., 2003).”
BackgroundPan, T., Zhang, R.-Z., Markova, D., Arita, M., Zhang, Y., Bogdanovich, S., Khurana, T. S., Bönnemann, C. G., Birk, D. E., & Chu, M. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.433078 · Cited by 76
“Physiological Measurements—Ex vivo physiological measurementswere performedondissected extensor digitorum longus (EDL) muscle from 4-month-old male mice as described (21, 22).”
MethodSelf-citationInhibiting myostatin reverses muscle fibrosis through apoptosis
Li, Z. B., Zhang, J., & Wagner, K. R. (2012) · Journal of Cell Science · doi:10.1242/jcs.090365 · Cited by 84
“…muscle have been developed, including neutralizing antibodies, derivatives of myostatin inhibitory propeptide, viral gene delivery of inhibitory follistatin and others (Bartoli et al., 2007; Bogdanovich et al., 2002; Lee, 2004; Nakatani et al., 2008; Qiao et al., 2008; Wagner et al., 2008).”
BackgroundInfluentialWilborn, C. D., Taylor, L. W., Campbell, B. I., Kerksick, C., Rasmussen, C. J., Greenwood, M., & Kreider, R. B. (2006) · Journal of the International Society of Sports Nutrition · doi:10.1186/1550-2783-3-2-19 · Cited by 73
Wetzlich, B., Nyakundi, B. B., & Yang, J. (2024) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-024-05120-y · Cited by 78
“…the targets of various MSTN inhibitors discussed in section “Inhibition of Myostatin in animal and human studies” ◂ in mdx mice resulted in enhancements in body weight, muscle mass, muscle size, and absolute muscle strength, accompanied by a significant reduction in muscle degeneration [41].”
Morine, K. J., Bish, L. T., Selsby, J. T., Gazzara, J. A., Pendrak, K., Sleeper, M. M., Barton, E. R., Lee, S., & Sweeney, H. L. (2010) · Muscle & Nerve · doi:10.1002/mus.21743 · Cited by 71
“Reduced serum CK was also observed in short-term studies of myostatin inhibition in mdx mice, although the mechanism of this benefit is unclear.(4,33,34) Activin receptor blockade resulted in increased weight of all skeletal muscles examined, with the exception of the soleus (Fig.”
BackgroundResultSelf-citationTeichmann, M. D. H., von Wegner, F., Fink, R., Chamberlain, J. S., Launikonis, B. S., Martinac, B., & Friedrich, O. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003644 · Cited by 75
“The model was suitable to develop pharmacological [4–6] or gene therapy strategies to possibly treat the dystrophic phenotype [7,8].”
MethodAbmayr, S., Gregorevic, P., Allen, J. M., & Chamberlain, J. S. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.04.001 · Cited by 71
Purification and identification of a BMP-like factor from bovine serum
Kodaira, K., Imada, M., Goto, M., Tomoyasu, A., Fukuda, T., Kamijo, R., Suda, T., Higashio, K., & Katagiri, T. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.05.045 · Cited by 72
Koncarevic, A., Cornwall-Brady, M., Pullen, A., Davies, M., Sako, D., Liu, J., Kumar, R., Tomkinson, K., Baker, T., Umiker, B., et al. (2010) · Endocrinology · doi:10.1210/en.2010-0134 · Cited by 71
Cellular mechanisms and local progenitor activation to regulate skeletal muscle mass
Cassano, M., Quattrocelli, M., Crippa, S., Perini, I., Ronzoni, F., & Sampaolesi, M. (2009) · Journal of Muscle Research and Cell Motility · doi:10.1007/s10974-010-9204-y · Cited by 77
Acetoacetate Accelerates Muscle Regeneration and Ameliorates Muscular Dystrophy in Mice
Zou, X., Meng, J., Li, L., Han, W., Li, C., Zhong, R., Miao, X., Cai, J., Zhang, Y., & Zhu, D. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.676510 · Cited by 71
“mdx mice, a model of human Duchenne muscular dystrophy, have been widely used to study the development of the disease and identify potential candidate drugs (63, 64).”
BackgroundLinkage of myostatin pathway genes with knee strength in humans
Huygens, W., Thomis, M. A., Peeters, M., Aerssens, J., Janssen, R. G. J. H., VLIETINCK, R. F., & Beunen, G. P. (2004) · Physiological Genomics · doi:10.1152/physiolgenomics.00224.2003 · Cited by 76
“The negative regulation of myostatin on postnatal muscle growth is confirmed by a study where a myostatin blocker, in vivo, increased muscle size and strength in mice suffering from Duchenne muscular dystrophy (5).”
Akt deficiency attenuates muscle size and function but not the response to ActRIIB inhibition
Goncalves, M. D., Pistilli, E. E., Balduzzi, A., Birnbaum, M. J., Lachey, J., Khurana, T. S., & Ahima, R. S. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012707 · Cited by 69
“Single-fiber cross-sectional area (CSA) and distribution were determined in images from tissue sections immunostained for laminin [39].”
BackgroundSelf-citationThe Intriguing Regulators of Muscle Mass in Sarcopenia and Muscular Dystrophy
Sakuma, K., Aoi, W., & Yamaguchi, A. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00230 · Cited by 69
“The use of neutralizing antibodies to myostatin improved muscle disorders in rodent models of DMD (mdx) and limb-girdle muscular dystrophy 2f (Sgcg−/−) (Bogdanovich et al., 2002; Bradley et al., 2008).”
BackgroundRybalka, E., Timpani, C. A., Debruin, D. A., Bagaric, R. M., Campelj, D. G., & Hayes, A. (2020) · Cells · doi:10.3390/cells9122657 · Cited by 73
“Many studies have shown that fibrosis of dystrophin deficient mdx skeletal muscles can be reduced through pharmacological myostatin inhibition [22,30,113,121,122], yet surprisingly, muscle quality (i.”
BackgroundAn Activin Mutant with Disrupted ALK4 Binding Blocks Signaling via Type II Receptors
Harrison, C. A., Gray, P. C., Fischer, W. H., Donaldson, C., Choe, S., & Vale, W. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m402782200 · Cited by 71
Increased Muscle Force Production and Bone Mineral Density in ActRIIB-Fc-Treated Mature Rodents
Chiu, C.-S., Peekhaus, N., Weber, H., Adamski, S., Murray, E. M., Zhang, H. Z., Zhao, J. Z., Ernst, R., Lineberger, J., Huang, L., et al. (2013) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/glt030 · Cited by 68
“The increase of muscle mass is due to hypertrophy rather than hyperplasia (12).”
BackgroundMOTS-c reduces myostatin and muscle atrophy signaling
Kumagai, H., Coelho, A. R., Wan, J., Mehta, H. H., Yen, K., Huang, A., Zempo, H., Fuku, N., Maeda, S., Oliveira, P. J., et al. (2021) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00275.2020 · Cited by 65
Lawlor, M. W., Read, B., Edelstein, R., Yang, N. J., Pierson, C. R., Stein, M. J., Wermer-Colan, A., Buj‐Bello, A., Lachey, J. L., Seehra, J. S., et al. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2010.10.035 · Cited by 69
Bernardo, B. L., Wachtmann, T. S., Cosgrove, P. G., Kuhn, M., Opsahl, A. C., Judkins, K. M., Freeman, T. B., Hadcock, J. R., & LeBrasseur, N. K. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011307 · Cited by 69
“, [23,24]) and even later life [17].”
Micro-dystrophin and follistatin co-delivery restores muscle function in aged DMD model
Rodino‐Klapac, L. R., Janssen, P. M. L., Shontz, K. M., Canan, B. D., Montgomery, C. L., Griffin, D., Heller, K. N., Schmelzer, L., Handy, C. R., Clark, K. R., et al. (2013) · Human Molecular Genetics · doi:10.1093/hmg/ddt342 · Cited by 70
Kinouchi, N., Ohsawa, Y., Ishimaru, N., Ohuchi, H., Sunada, Y., Hayashi, Y., Tanimoto, Y., Moriyama, K., & Noji, S. (2008) · Gene Therapy · doi:10.1038/gt.2008.24 · Cited by 68
Randomized phase 2 trial and open-label extension of domagrozumab in Duchenne muscular dystrophy
Wagner, K. R., Abdel-Hamid, H. Z., Mah, J. K., Campbell, C., Guglieri, M., Muntoni, F., Takeshima, Y., McDonald, C. M., Kostera-Pruszczyk, A., Karachunski, P., et al. (2020) · Neuromuscular Disorders · doi:10.1016/j.nmd.2020.05.002 · Cited by 67
“Loss or inhibition of myostatin in mdx mouse DMD models leads to increased muscle mass, increased strength, and decreased fat substitution and fibrosis [4-11] .”
Arounleut, P., Bialek, P., Liang, L.-F., Upadhyay, S., Fulzele, S., Johnson, M., Elsalanty, M., Isales, C. M., & Hamrick, M. W. (2013) · Experimental Gerontology · doi:10.1016/j.exger.2013.06.004 · Cited by 66
“These include utilization of myostatin-specific antibodies (Bogdanovich et al., 2002; LeBrasseur et al., 2009;Murphy et al., 2010;Wagner et al., 2008), a decoymyostatin receptor (ActRIIB-Fc; Bialek et al., 2008; Borgstein et al., 2009; Chiu et al., 2013; Lee et al., 2005), and myostatin propeptide…”
BackgroundDoran, P., Wilton, S. D., Fletcher, S., & Ohlendieck, K. (2009) · PROTEOMICS · doi:10.1002/pmic.200800441 · Cited by 77
Jespersen, J. G., Nedergaard, A., Andersen, L. L., Schjerling, P., & Andersen, J. L. (2011) · Scandinavian Journal of Medicine & Science in Sports · doi:10.1111/j.1600-0838.2009.01044.x · Cited by 67
“Moreover, postnatal inhibition of myostatin increases skeletal muscle mass (Bogdanovich et al., 2002; Whittemore et al., 2003; Lee et al., 2005; Welle et al., 2007; Sartori et al., 2009).”
BackgroundGlucocorticoids Enhance Muscle Proteolysis through a Myostatin-Dependent Pathway at the Early Stage
Wang, R., Jiao, H., Zhao, J., Wang, X., & Lin, H. (2016) · PLoS ONE · doi:10.1371/journal.pone.0156225 · Cited by 74
“A blockade of endogenous myostatin results in an adverse increase in muscle mass and size and a decrease in muscle degeneration in an X chromosome-linked muscular dystrophy (mdx) mouse-model of Duchenne muscular dystrophy [12].”
BackgroundReduced serum myostatin concentrations associated with genetic muscle disease progression
Burch, P. M., Pogoryelova, O., Palandra, J., Goldstein, R., Bennett, D., Fitz, L. J., Guglieri, M., Marini‐Bettolo, C., Straub, V. W., Evangelista, T., et al. (2017) · Journal of Neurology · doi:10.1007/s00415-016-8379-6 · Cited by 71
“controls, numerous studies have shown that anti-myostatin therapies increase muscle mass and strength in this DMD model [6, 20, 21].”
Facioscapulohumeral Muscular Dystrophy
DeSimone, A. M., Pakuła, A., Lek, A., & Emerson, C. P. (2017) · Comprehensive physiology · doi:10.1002/cphy.c160039 · Cited by 72
Powerful Genes — Myostatin Regulation of Human Muscle Mass
McNally, E. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmp048124 · Cited by 68
Li, Z., Shelton, G. D., & Engvall, E. (2005) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)62271-7 · Cited by 74
Myostatin as a therapeutic target for musculoskeletal disease
Bradley, L., Yaworsky, P. J., & Walsh, F. S. (2008) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-008-8077-3 · Cited by 74
Kunkel, L. M. (2005) · The American Journal of Human Genetics · doi:10.1086/428143 · Cited by 71
Murphy, K. T., Ryall, J. G., Snell, S. M., Nair, L., Koopman, R., Krasney, P. A., Ibebunjo, C., Holden, K. S., Loria, P. M., Salatto, C. T., et al. (2010) · American Journal Of Pathology · doi:10.2353/ajpath.2010.090932 · Cited by 72
“The inhibition of myostatin using the antibody, JA-16, has been shown previously to increase muscle mass by 23% to 35% in 4- to 8-week-old wild-type(13) and dystrophic mdx mice.(19) In the present study, we demonstrated the efficacy of the myostatin inhibitory antibody, PF-354, for inhibiting myostatin induced transcr…”
BackgroundResultHypercatabolism in dialysis patients
Raj, D. S., Sun, Y., & Tzamaloukas, A. H. (2008) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0b013e32830d5bfa · Cited by 66
Nguyen, M.-A. T., Joya, J. E., Kee, A. J., Domazetovska, A., Yang, N., Hook, J., Lemckert, F. A., Kettle, E., Valova, V. A., Robinson, P. J., et al. (2011) · Brain · doi:10.1093/brain/awr274 · Cited by 73
“…and immobility of the Acta1(H40Y) mice Induction of muscle hypertrophy has been shown to improve muscle strength and reduce disease pathology in a number of different models of muscular dystrophy (Barton et al., 2002; Bogdanovich et al., 2002; Gregorevic et al., 2002; Parsons et al., 2006).”
Sato, F., Kurokawa, M., Yamauchi, N., & Hattori, M. (2006) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00543.2005 · Cited by 69
“The blockage of endogenously produced GDF-8 action in mdx mice greatly improved dystrophic muscle (4, 37, 38).”
BackgroundNew therapies for muscular dystrophy: cautious optimism
Cossu, G., & Sampaolesi, M. (2004) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2004.08.007 · Cited by 70
Evidence for ACTN3 as a genetic modifier of Duchenne muscular dystrophy
Hogarth, M. W., Houweling, P. J., Thomas, K. C., Gordish‐Dressman, H., Bello, L., Vishwanathan, V., Chidambaranathan, S., Biggar, W. D., McAdam, L. C., Mah, J. K., et al. (2017) · Nature Communications · doi:10.1038/ncomms14143 · Cited by 78
Goh, B. C., Singhal, V., Herrera, A. J., Tomlinson, R. E., Kim, S., Faugere, M.-C., Germain-Lee, E. L., Clemens, T. L., Lee, S.-J., & DiGirolamo, D. J. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.782128 · Cited by 63
Principles of the activin receptor signaling pathway and its inhibition
Lodberg, A. (2021) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2021.04.001 · Cited by 62
Systemic Myostatin Inhibition via Liver-Targeted Gene Transfer in Normal and Dystrophic Mice
Morine, K. J., Bish, L. T., Pendrak, K., Sleeper, M. M., Barton, E. R., & Sweeney, H. L. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009176 · Cited by 64
“strated increased muscle mass and absolute force production following 3–4 months of myostatin inhibition in young animals (1– 3 months old) [3,13,14].”
BackgroundResultInfluentialSelf-citationSingle muscle fiber contractile properties in adults with muscular dystrophy treated with MYO‐029
Krivickas, L. S., Walsh, R., & Amato, A. A. (2009) · Muscle & Nerve · doi:10.1002/mus.21200 · Cited by 61
Harcourt, L. J., Holmes, A. G., Gregorevic, P., Schertzer, J. D., Stupka, N., Plant, D. R., & Lynch, G. S. (2005) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)62333-4 · Cited by 63
Sprinting without myostatin: a genetic determinant of athletic prowess
Lee, S. (2007) · Trends in Genetics · doi:10.1016/j.tig.2007.08.008 · Cited by 69
“Several such agents have been shown to be effective in increasing muscle growth in mice [ 13 ,15,16,19,23] ,a nd one of these, a neutralizing monoclonal activity directed against MSTN, is currently being tested in a clinical trial in patients with adult forms of muscular dystrophy.”
BackgroundExercise and muscle dysfunction in COPD: implications for pulmonary rehabilitation
Man, W. D., Kemp, P. R., Moxham, J., & Polkey, M. I. (2009) · Clinical Science · doi:10.1042/cs20080660 · Cited by 67
Duchenne muscular dystrophy gene therapy: Lost in translation?
Duan, D. (2011) · Research and Reports in Biology · doi:10.2147/rrb.s13463 · Cited by 56
Hormone abuse in sports: the antidoping perspective
Barroso, O., Mazzoni, I., & Rabin, O. (2008) · Asian Journal of Andrology · doi:10.1111/j.1745-7262.2008.00402.x · Cited by 59
Gene Therapy for Duchenne Muscular Dystrophy: Expectations and Challenges
Rodino‐Klapac, L. R., Chicoine, L. G., Kaspar, B. K., & Mendell, J. R. (2007) · Archives of Neurology · doi:10.1001/archneur.64.9.1236 · Cited by 73
Lack of toxicity of alpha-sarcoglycan overexpression supports clinical gene transfer trial in LGMD2D
Rodino-Klapac, L. R., Lee, J.-S., Mulligan, R. C., Clark, K. R., & Mendell, J. R. (2008) · Neurology · doi:10.1212/01.wnl.0000306309.85301.e2 · Cited by 60
Mozzetta, C., Sartorelli, V., & Puri, P. (2024) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2024.01.007 · Cited by 67
Myostatin inhibitors as pharmacological treatment for muscle wasting and muscular dystrophy
Saitoh, M., Ishida, J., Ebner, N., Anker, S. D., Springer, J., & von Haehling, S. (2017) · JCSM Clinical Reports · doi:10.17987/jcsm-cr.v2i1.37 · Cited by 57
Muscle regeneration through myostatin inhibition
Wagner, K. R. (2005) · Current Opinion in Rheumatology · doi:10.1097/01.bor.0000184163.61558.ca · Cited by 65
Gene Therapy in Large Animal Models of Muscular Dystrophy
Wang, Z., Chamberlain, J. S., Tapscott, S. J., & Storb, R. F. (2009) · ILAR Journal · doi:10.1093/ilar.50.2.187 · Cited by 68
“…Journal expression of utrophin (a homologue of dystrophin) to compensate for impaired dystrophin function or (2) to inhibit myostatin (a negative regulator of muscle growth) and thus increase muscle mass (Bogdanovich et al. 2002; Fisher et al. 2001; Qiao et al. 2008, 2009; Wakefi eld et al. 2000).”
BackgroundProfibrotic Role of Myostatin in Peyronie's Disease
Cantini, L. P., Ferrini, M. G., Vernet, D., Magee, T. R., Qian, A., Gelfand, R. A., Rajfer, J., & Gonzalez-Cadavid, N. F. (2008) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2008.00847.x · Cited by 59
Xu, R., Chandrasekharan, K., Yoon, J. H., Camboni, M., & Martin, P. T. (2007) · American Journal Of Pathology · doi:10.2353/ajpath.2007.060927 · Cited by 63
“For example, therapies including myostatin inhibition and ADAM12 overexpression were not effective in dy/dy muscles,(39,40) despite the fact that they did have a positive impact on mdx muscle pathology.(13,24,33,34,91) Although beyond the scope of the current study, it will be of interest to determine the extent to wh…”
MethodNovel Intriguing Strategies Attenuating to Sarcopenia
Sakuma, K., & Yamaguchi, A. (2012) · Journal of Aging Research · doi:10.1155/2012/251217 · Cited by 69
“The use of neutralizing antibodies to myostatin improved muscle disorders in rodent models of Duchenne muscular dystrophy (DMD), limb girdle muscular dystrophy 2F (Sgcg−/−), and amyotrophic lateral sclerosis (SOD1G93A transgenic mouse) [27, 28, 42, 43].”
BackgroundAcute antibody-directed myostatin inhibition attenuates disuse muscle atrophy and weakness in mice
Murphy, K. T., Cobani, V., Ryall, J. G., Ibebunjo, C., & Lynch, G. S. (2011) · Journal of Applied Physiology · doi:10.1152/japplphysiol.01183.2010 · Cited by 58
“Several studies have highlighted the therapeutic potential of myostatin inhibition for enhancing skeletal muscle mass and function in conditions associated with muscle wasting and weakness, including the muscular dystrophies (5, 27, 35), sarcopenia (26, 31, 32), and cancer cachexia (3, 37).”
BackgroundActivin receptor antagonists for cancer-related anemia and bone disease
Fields, S. Z., Parshad, S., Anne, M., Raftopoulos, H., Alexander, M. J., Sherman, M. L., Laadem, A., Sung, V., & Terpos, E. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2013.738666 · Cited by 58
“Neutralizing antibodies have been used in vivo to inhibit the formation of functional complexes between activins or GDF8 and activin receptors (Figure 2) [69,70].”
BackgroundHistone Deacetylases: Molecular Mechanisms and Therapeutic Implications for Muscular Dystrophies
Sandonà, M., Cavioli, G., Renzini, A., Cedola, A., Gigli, G., Coletti, D., McKinsey, T. A., Moresi, V., & Saccone, V. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054306 · Cited by 65
Myostatin induces interstitial fibrosis in the heart via TAK1 and p38
Biesemann, N., Mendler, L., Sawa Kostin, D., Wietelmann, A., Borchardt, T., & Braun, T. W. (2015) · Cell and Tissue Research · doi:10.1007/s00441-015-2139-2 · Cited by 58
Thevis, M., & Schänzer, W. (2014) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2014.05.020 · Cited by 61
Myostatin: a therapeutic target for skeletal muscle wasting
Roth, S. M., & Walsh, S. (2004) · Current Opinion in Clinical Nutrition and Metabolic Care · doi:10.1097/00075197-200405000-00004 · Cited by 58
Gene therapy for muscular dystrophy: current progress and future prospects
Trollet, C., Athanasopoulos, T., Popplewell, L. J., Malerba, A., & Dickson, G. (2009) · Expert Opinion on Biological Therapy · doi:10.1517/14712590903029164 · Cited by 62
“These treatments could be categorized in either pharmacological strategies (monoclonal antibody [102-104], soluble receptor [105,106], propeptide [107]) or gene therapy strategies.”
Iskenderian, A., Liu, N., Deng, Q., Huang, Y. L., Shen, C., Palmieri, K. J., Crooker, R., Lundberg, D. M., Kastrapeli, N., Pescatore, B., et al. (2018) · Skeletal Muscle · doi:10.1186/s13395-018-0180-z · Cited by 59
DiGirolamo, D. J., Singhal, V., Chang, X., Lee, S.-J., & Germain-Lee, E. L. (2015) · Bone Research · doi:10.1038/boneres.2014.42 · Cited by 56
Cozzoli, A., Capogrosso, R. F., Sblendorio, V. T., Dinardo, M. M., Jagerschmidt, C., Namour, F., Camerino, G. M., & Luca, A. D. (2013) · Pharmacological Research · doi:10.1016/j.phrs.2013.03.003 · Cited by 64
The possible role of myostatin in skeletal muscle atrophy and cachexia
Jespersen, J., Kjær, M., & Schjerling, P. (2005) · Scandinavian Journal of Medicine and Science in Sports · doi:10.1111/j.1600-0838.2005.00498.x · Cited by 60
“A relationship between myostatin and these Smads has earlier been established, evidenced by a decreased concentration of phosphorylated Smad2 and 3 in C2C12 cells treated with the JA16 myostatin antibody (Bogdanovich et al., 2002).”
BackgroundInfluentialMyostatin — From the Mighty Mouse to cardiovascular disease and cachexia
Dschietzig, T. B. (2014) · Clinica Chimica Acta · doi:10.1016/j.cca.2014.03.021 · Cited by 58
“Since then, this outstanding discovery has ignited enormous scientific and economic interest, for obvious reasons: In man, the development of myostatin-inactivating therapies holds great promise to patients suffering from cachexia, muscle dystrophy, or trauma [6,7].”
BackgroundROLE OF CONTRACTION‐INDUCED INJURY IN THE MECHANISMS OF MUSCLE DAMAGE IN MUSCULAR DYSTROPHY
Lynch, G. S. (2004) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.2004.04026.x · Cited by 62
Metadata
- Authors
- Bogdanovich, S., Krag, T. O. B., Barton, E. R., Morris, L. D., Whittemore, L.-A., Ahima, R. S., & Khurana, T. S.
- Affiliations
- University of Pennsylvania (US)
- Pfizer (United States) (US)
- Corresponding author
- Khurana, Tejvir S.
- Venue
- Nature
- Published
- 2002-11
- Volume
- 420
- Issue
- 6914
- Pages
- 418-421
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2083700023
- Semantic Scholar
- 590fb54cd1f2d89d44f4e1ad999be802dc756277
- Cited by
- 831
- References
- 31
- Citations by year
- 2026: 11 · 2025: 12 · 2024: 19 · 2023: 15 · 2022: 21 · 2021: 20 · 2020: 23 · 2019: 32 · 2018: 23 · 2017: 34 · 2016: 28 · 2015: 43 · 2014: 34 · 2013: 38 · 2012: 48
- FWCI
- 12.98
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Institutes of Health
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
- Health Sciences › Medicine › Genetics (clinical) › Neurogenetic and Muscular Disorders Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiomyopathy and Myosin Studies
- Keywords
- myostatin, Duchenne muscular dystrophy, mdx mice, muscle atrophy, blocking antibodies, muscle mass, muscle strength, muscle degeneration, creatine kinase, TGF-beta superfamily, skeletal muscle growth
- MeSH terms
- Animals, Antibodies, Body Weight, Creatine Kinase, Male, Muscular Dystrophy, Animal, Organ Size, Transforming Growth Factor beta, Mice, Inbred mdx, Muscle, Skeletal, Muscle Fibers, Skeletal, Muscular Dystrophy, Duchenne, Mice, Myostatin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.